IT has been a good quarter for
GlaxoSmithKline, with the
manufacturer seeing its Q3 profits
up 7% on last year’s results to
$2.13 billion.
The increase has been attributed
in part to sales growth in Japan
which was up 57%, as well as
growth in its emerging markets
of 11%.
Top performing areas included
vaccine sales which jumped 16%,
whilst its asthma drug Advair
(seretide) was responsible for 23%
of the company’s overall vaccine
and pharmaceutical sales.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Oct 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Oct 11
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.